Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome

NCT00587860
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
St. John's wort, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Effects of an Intermittent Reduced Calorie Diet on Crohn's Disease

NCT04147585
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Diet Modification
Interventions
Intermittent Reduced Calorie Diet (IRCD)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

NCT03806127
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Vibegron, Placebo
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Not applicable Interventional

Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS

NCT00219505
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
acupuncture
Procedure
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04677179
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Litchfield Park, Arizona • Kissimmee, Florida • Pensacola, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Sex Differences in Effectiveness of CBT on IBS Project 3

NCT05155631
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome
Interventions
COGNITIVE BEHAVIORAL THERAPY
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

NCT02251483
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

NCT00038766
View directory record Official record
Conditions
Crohn Disease
Interventions
semapimod, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
San Diego, California • Gainesville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 21, 2026, 3:57 AM EDT
Completed No phase listed Observational

IBD-OPERA Database, UC Protocol

NCT01708395
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 17, 2015 · Synced Oct 21, 2026, 3:57 AM EDT
Suspended No phase listed Observational

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

NCT05252273
View directory record Official record
Conditions
Pouchitis, Ulcerative Colitis
Interventions
Observational, No intervention
Other
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS

NCT02847481
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
fecal microbiota transplantation, placebo fecal microbiota transplantation, FMT with antibiotic pre-treatment (v1), FMT with antibiotic pre-treatment (v2)
Procedure · Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 2Phase 3 Interventional

The Role of Secondary Bile Acids in Intestinal Inflammation

NCT03724175
View directory record Official record
Conditions
Ulcerative Colitis, Pouchitis
Interventions
ursodiol (ursodeoxycholic acid, UDCA)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

NCT01890837
View directory record Official record
Conditions
Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Abdominal Pain
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

NCT03345836
View directory record Official record
Conditions
Crohn's Disease
Interventions
Matching Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
119
States / cities
Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Oct 21, 2026, 3:57 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

NCT03167437
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vorinostat, Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653
View directory record Official record
Conditions
Crohn's Disease
Interventions
abatacept, placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)

NCT04779307
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Recruiting Phase 4 Interventional

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

NCT06581328
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab IV, Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 3:57 AM EDT
Active, not recruiting No phase listed Observational

The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis

NCT02389075
View directory record Official record
Conditions
Inflammatory Bowel Diseases (IBD), Ankylosing Spondylitis (AS)
Interventions
Pinch biopsies, Flexible sigmoidoscopy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Symptom Management for Irritable Bowel Syndrome

NCT02079857
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Standard protocol, Individualized protocol, Sham acupuncture/Placebo moxa
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Not applicable Interventional

MD2Me - Texting to Promote Chronic Disease Management

NCT01253733
View directory record Official record
Conditions
Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
Interventions
MD2ME
Behavioral
Lead sponsor
Huang, Jeannie, M.D.
Individual
Eligibility
14 Years to 22 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 21, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

NCT02093663
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
Drug
Lead sponsor
Shire
Industry
Eligibility
5 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 3:57 AM EDT
Completed No phase listed Observational

Efficacy of Psychological Therapies in Patients With Functional Bowel Disorders

NCT04060121
View directory record Official record
Conditions
IBS - Irritable Bowel Syndrome, Constipation
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 21, 2026, 3:57 AM EDT